The isoenzymes of MAO-A and MAO-B are considered major therapeutic targets in various neuropsychiatric illnesses and neurodegenerative disorders like Alzheimer’s disease (AD) and Parkinson’s disease (PD).5 Here, MAOB is linked to early-onset autosomal dominant Alzheimer disease.